×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARCT – arcturus therapeutics holdings inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARCT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
08:15 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.
Medium
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.
12/16
04:01 pm
arct
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/16
08:30 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/11
12:10 pm
arct
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers [Yahoo! Finance]
Low
Report
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers [Yahoo! Finance]
11/26
04:01 pm
arct
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Medium
Report
Arcturus Therapeutics to Attend Upcoming Investor Conferences
11/21
03:36 am
arct
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans [Yahoo! Finance]
Medium
Report
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans [Yahoo! Finance]
11/18
08:00 pm
arct
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Medium
Report
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
11/14
01:00 am
arct
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Medium
Report
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
04:01 pm
arct
arcturus therapeutics holdings inc.
BEAT
Report
4.7%
arcturus therapeutics holdings inc.
8/5/2024
04:01 pm
arct
arcturus therapeutics holdings inc.
BEAT
Report
0.2%
arcturus therapeutics holdings inc.
5/8/2024
04:01 pm
arct
arcturus therapeutics holdings inc.
BEAT
Report
-1.5%
arcturus therapeutics holdings inc.
3/7/2024
04:01 pm
arct
arcturus therapeutics holdings inc.
BEAT
Report
-0.9%
arcturus therapeutics holdings inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/18
04:07 pm
arct
Form 4 Arcturus Therapeutics For: Dec 16 Filed by: Payne Joseph E
Low
Report
Form 4 Arcturus Therapeutics For: Dec 16 Filed by: Payne Joseph E
12/18
04:07 pm
arct
Form 4 Arcturus Therapeutics For: Dec 16 Filed by: Chivukula Pad
Low
Report
Form 4 Arcturus Therapeutics For: Dec 16 Filed by: Chivukula Pad
12/18
04:07 pm
arct
Form 4 Arcturus Therapeutics For: Dec 16 Filed by: Kurata Lance
Low
Report
Form 4 Arcturus Therapeutics For: Dec 16 Filed by: Kurata Lance
12/18
04:06 pm
arct
Form 4 Arcturus Therapeutics For: Dec 16 Filed by: SASSINE ANDY
Low
Report
Form 4 Arcturus Therapeutics For: Dec 16 Filed by: SASSINE ANDY
11/8
03:18 pm
arct
Form SC 13G Arcturus Therapeutics Filed by: Nikko Asset Management Americas, Inc.
Low
Report
Form SC 13G Arcturus Therapeutics Filed by: Nikko Asset Management Americas, Inc.
11/7
05:06 pm
arct
Form 10-Q Arcturus Therapeutics For: Sep 30
Low
Report
Form 10-Q Arcturus Therapeutics For: Sep 30
11/7
04:28 pm
arct
Form 8-K Arcturus Therapeutics For: Nov 07
Medium
Report
Form 8-K Arcturus Therapeutics For: Nov 07
11/5
06:07 am
arct
Form SC 13G Arcturus Therapeutics Filed by: Sumitomo Mitsui Trust Group, Inc.
Low
Report
Form SC 13G Arcturus Therapeutics Filed by: Sumitomo Mitsui Trust Group, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/27
Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
29.7%
3/15 Arcturus Therapeutics Holdings Inc. Analysts Are Pretty Bullish On The Stock After Recent Results [Yahoo! Finance News] 22.1%
3/23 Form SEC STAFF LETTER Arcturus Therapeutics 19.3%
3/4 Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™ 15.7%
8/15 Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 14.3%
3/5 Arcturus Therapeutics Ltd (NASDAQ: ARCT) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating. 14.1%
7/30 Form EFFECT Arcturus Therapeutics 12.5%
6/20 Form 8-K Arcturus Therapeutics For: Jun 18 Filed by: Arcturus Therapeutics Holdings Inc. 12.3%
9/23 Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors 11.9%
6/20 Arcturus Therapeutics Ltd (NASDAQ: ARCT) was given a new $18.00 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. 11.3%
3/15 Arcturus Therapeutics Holdings Inc. Analysts Are Pretty Bullish On The Stock After Recent Results [Yahoo! Finance News] 22.1%
3/23 Form SEC STAFF LETTER Arcturus Therapeutics 19.3%
3/4 Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™ 15.7%
8/15 Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 14.3%
3/5 Arcturus Therapeutics Ltd (NASDAQ: ARCT) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating. 14.1%
7/30 Form EFFECT Arcturus Therapeutics 12.5%
6/20 Form 8-K Arcturus Therapeutics For: Jun 18 Filed by: Arcturus Therapeutics Holdings Inc. 12.3%
9/23 Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors 11.9%
6/20 Arcturus Therapeutics Ltd (NASDAQ: ARCT) was given a new $18.00 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. 11.3%
TOP News Decliners
3/12
Arcturus Therapeutics Holdings, Inc. (ARCT) CEO Joseph Payne on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-29.3%
4/28 Thinking about trading stocks or options in Arcturus Therapeutics, Laboratory Corp. of America, Bed Bath & Beyond, Moderna, or Zillow? -13.4%
3/27 Form 8-K Arcturus Therapeutics For: Mar 27 -13.2%
5/10 Q1/2019 3/31/2019 EPS -0.680 ZacksConsensus N/A ActVsEst N/A - N/A -13.2%
8/5 Form 424B5 Arcturus Therapeutics -12.9%
8/1 Form 8-K Arcturus Therapeutics For: Aug 01 -12.1%
8/15 Q2/2019 6/30/2019 EPS -0.070 ZacksConsensus -0.530 ActVsEst 0.460 - Beat -11.9%
9/26 Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock -9.8%
3/19 Arcturus Therapeutics Ltd (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $26.00 price target on the stock. -8.4%
2/24 Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11 -8.1%
4/28 Thinking about trading stocks or options in Arcturus Therapeutics, Laboratory Corp. of America, Bed Bath & Beyond, Moderna, or Zillow? -13.4%
3/27 Form 8-K Arcturus Therapeutics For: Mar 27 -13.2%
5/10 Q1/2019 3/31/2019 EPS -0.680 ZacksConsensus N/A ActVsEst N/A - N/A -13.2%
8/5 Form 424B5 Arcturus Therapeutics -12.9%
8/1 Form 8-K Arcturus Therapeutics For: Aug 01 -12.1%
8/15 Q2/2019 6/30/2019 EPS -0.070 ZacksConsensus -0.530 ActVsEst 0.460 - Beat -11.9%
9/26 Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock -9.8%
3/19 Arcturus Therapeutics Ltd (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $26.00 price target on the stock. -8.4%
2/24 Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11 -8.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: